All-Case Surveillance of Prizbind®

Boehringer Ingelheim

Status: Completed

Conditions: Hemorrhage

Treatments: Drug: Prizbind®

Study type: Observational

Funder types: Industry

Identifiers

NCT02946931

1321.15

Details and patient eligibility

About

To evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition.

Enrollment: 1,402 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients who are prescribed with Prizbind® for Intravenous Solution 2.5 g by the discretion of investigators

Exclusion criteria

None

Trial design

1,402 participants in 1 patient group

Prizbind® for Intravenous Solution

Description:

Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

Treatment:

Drug: Prizbind®